FDA’s Go-To Statistician: UW’s Fleming Holds Court At Xifaxan Advisory Committee Meeting
This article was originally published in RPM Report
University of Washington statistician Thomas Fleming seems to be showing up more often on FDA advisory committees and is having an outsized impact on the meetings.
You may also be interested in...
Going into the Avandia re-review, FDA looked stuck between a rock and a hard place. Coming out of the FDA advisory committee meeting, the agency has a full set of options to choose from that would likely be viewed as a credible outcome by the public. But possible surprises remain.
Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment.
Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.